When the federal government announced plans to move cannabis from Schedule I to Schedule III, the reaction was immediate. Headlines called it historic. Markets jumped. Once again, expectations surged.
But for most people working in and around cannabis today, the reality is quieter and far more complicated. Cannabis rescheduling is not the same as full legalization, nor is it the same as descheduling.
Rescheduling matters. It signals a long-overdue shift in how the federal government views cannabis. At the same time, it does not rewrite the rules overnight or fix the structural problems that have defined the legal market for decades.
Understanding the difference is key. And knowing that Old Pal is still—and always—pushing for legalization.
What Changed with the Rescheduling
For the first time since the Controlled Substances Act was passed in 1970, the federal government is formally acknowledging that cannabis has accepted medical use.
Schedule I has always been the most restrictive category, reserved for substances the government claimed had no medical value and a high potential for abuse. Cannabis was placed there alongside drugs like heroin and LSD, despite decades of patient use and mounting scientific evidence to the contrary.
Moving cannabis to Schedule III recognizes medical reality. It aligns federal policy more closely with the fact that most U.S. states now operate medical marijuana programs and millions of patients use cannabis under a doctor’s recommendation.
Just as importantly, it changes the tone of the conversation. The announcement was framed around pain management, seniors, veterans, and end-of-life care. Cannabis was presented as a medical tool, not a cultural statement.
That shift in framing helped make this moment possible.
“I’d prefer to see descheduling to rescheduling, but for me I will take whatever we can get in terms of federal progress,” said Rusty Wilenken, Old Pal founder, in a recent interview with BevNet. “I hope to see a thriving industry with less restrictions at both the state and federal level, cannabis businesses able to operate like normal companies, and the stigma to start to fade.”
What Hasn’t Changed
Rescheduling is not legalization. It does not open dispensaries nationwide, normalize adult use, or end federal prohibition.
For cannabis operators, the most important limitations remain firmly in place.
Taxes stay the same, for now.
Until rescheduling is finalized through federal rulemaking, cannabis businesses remain subject to IRS code 280E, which blocks standard business deductions and inflates operating costs. Even if Schedule III eventually takes effect, relief would apply going forward, not retroactively.
Rusty weighed in with his optimism, anchored by the reality of what rescheduling truly means for the cannabis industry, particularly as we look toward the removal of 280E.
“[Rescheduling] would make the cannabis industry viable/profitable overnight,” said Rusty. “The tax implications of 280e and the implications of not being able to deduct below-the-line expenses are brutal, resulting in effective tax rates as high as 75%. To the extent these businesses could take deductions that normal businesses take [and] bank like normal businesses bank and have access to capital at competitive rates, everything changes.”
Banking is still a challenge.
Rescheduling alone does not give banks a green light to fully serve cannabis businesses. Without separate legislation or clearer enforcement protections, financial institutions still face risk.
Interstate commerce remains off the table.
State-licensed operators are still confined within state borders. Schedule III does not legalize interstate cannabis sales or unify the fragmented market.
Federal access requires federal compliance.
The benefits of Schedule III are tied to FDA approval and DEA registration. Most products sold in today’s adult-use markets were never designed for that system. Flower, concentrates, and many edibles would not automatically qualify.
In other words, the existing state-legal market does not suddenly become federally legal.
Who Does This Actually Help Right Now
In the near term, rescheduling benefits a narrower group than many headlines suggest.
The clearest winners are researchers, pharmaceutical developers, and federally compliant manufacturers with the resources to pursue FDA-approved cannabinoid drugs. Schedule III lowers barriers to clinical research and formal drug development.
State-licensed dispensaries and adult-use brands see far fewer immediate gains. Their products remain federally illegal without approval. Their banking issues remain unresolved. Their tax burden stays heavy until a final rule is completed.
Rescheduling opens doors, but only for those already positioned to walk through federal systems.
“I think the broad attitude around cannabis is acceptance, and that the government is lagging the people on this one. While I imagine a more legal industry would lead to more tolerance and acceptance across the country, at the consumer level it isn’t needed to see the industry continue to thrive. The consumers are there and want this product, the government needs to let them have it.”
-Rusty Wilenken, OId Pal Founder
Why the Framing Matters
One of the most revealing parts of this moment is how carefully cannabis was separated from culture.
There was no celebration of legalization, no nod to dispensaries or consumer brands, and no language tied to lifestyle or identity. Cannabis was treated like any other tightly regulated medical substance: useful, powerful, and deserving of oversight.
That choice helped neutralize decades of political resistance. It also raises real questions about where consumer cannabis fits into a future shaped by federal regulators and pharmaceutical standards.
Schedule III brings cannabis closer to the FDA’s orbit. That creates tension for an industry built around accessibility and state-level experimentation rather than prescription-only models.
Those conflicts won’t be resolved by an executive order.
Rescheduling is not a finish line. It’s a step in a long, contested process that includes litigation, rulemaking, and political pushback.
It acknowledges what patients and advocates have known for years: cannabis has medical value. At the same time, it leaves the core contradictions of U.S. cannabis policy intact.
State markets continue to grow. Federal law continues to lag behind. Consumers and operators still live in the space between.
The Bottom Line
Cannabis rescheduling matters because it signals movement, not because it delivers instant change.
It does not legalize cannabis. It does not fix taxes, banking, or interstate commerce. It does not guarantee protection for the businesses that built this industry under state law.
What it does do is mark a shift in how the federal government talks about cannabis and why it can no longer ignore its medical reality. That recognition is real—and long overdue.
At the same time, the gap between federal policy and state markets remains wide. Cannabis is acknowledged as medicine, while the industry that already exists is largely left to navigate the risks on its own.
Progress is real. So are the limits. Until federal law fully aligns with how cannabis is actually used, sold, and regulated in this country, rescheduling will remain a signal—not a solution.
